• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Naltrexone-bupropion may reduce adverse cardiovascular events in obese patients

byJohn PrendergassandMichael Milligan
March 8, 2016
in Cardiology, Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Based on interim analysis after 25% and 50% of expected events, among obese patients naltrexone-bupropion treatment resulted in lower risk of first major adverse cardiovascular event and cardiovascular death.

2. The most common events leading to discontinuation of therapy included GI and CNS symptoms, which occurred more often in the treatment group.

Evidence Rating Level: 2 (Good)       

Study Rundown: According to the CDC, more than one third of U.S. adults are considered obese, a proportion that continues to rise. Obesity related conditions such as heart disease, stroke, type 2 diabetes, and some forms of cancer are a few of the leading causes of preventable death. The cost of treating obesity and its related conditions is upwards of $147 billion. Consequently, numerous treatments for the condition have been trialed over the years, both to decrease total weight and associated major adverse cardiovascular events (MACE). Two agents studied, naltrexone and bupropion, have been shown to reduce weight in a phase 3 clinical trial, but may have been associated with adverse cardiovascular side effects.

The FDA required more research into the safety of these drugs, and thus this study examined whether the combination of naltrexone and bupropion increased major cardiovascular events (cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) in overweight and obese patients compared to placebo. An interim analysis found that MACE occurred in more placebo treated patients than in the naltrexone-bupropion group after 25% and 50% of the total predicted events. However, GI and CNS side effects were more common in the pharmacological group. Key strengths of the study include the randomized, multicenter, double-blind and placebo-controlled design. This study is weakened by its early termination and consequent inability to properly assess noninferiority for the FDA mandated limit of a 1.4 hazard ratio. Consequently, further research is still needed to completely evaluate the safety of these potentially beneficial pharmacological agents.

Click to read the study in JAMA

Relevant Reading: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

RELATED REPORTS

Subsidization of supermarkets may help reduce obesity risk in children

Wellness Check: Nutrition

Review suggests mixed evidence for relationship between food insecurity and childhood obesity

In-Depth [randomized controlled trial]: This randomized clinical trial evaluated 8,910 participants over a total follow up of 2-4 years. Mean age of the randomized patients was 61, with 54.5% being women and 83.5% being described as white. First MACE occurred in 2.3% of the placebo group and 2.0% of the naltrexone-bupropion group (HR 0.88; 99.7%CI 0.57-1.34). Cardiovascular death occurred in 0.8% of the placebo group and 0.4% of the treatment group (HR 0.50; 99.7%CI 0.21-1.19). Nonfatal stroke occurred in 0.4% of the placebo group and 0.5% of the treatment group (HR 1.32; 99.7%CI 0.57-3.08). Nonfatal myocardial infarction occurred in 1.2% of the placebo group and 1.2% of the treatment group (HR 1.01; 99.7%CI 0.61-1.66). Most common events leading to discontinuation include GI events, occurring in 1.9% of the placebo group and 14.2% of the treatment group (p < 0.001) and CNS symptoms, occurring in 1.2% of the placebo group and 5.1% of the treatment group (p < 0.001).

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascularobesity
Previous Post

Low aerobic capacity and strength in youth associated with increased risk of diabetes in adulthood

Next Post

American Academy of Pediatrics calls for action on poverty

RelatedReports

Meeting families, demographic information affect child abuse work-up
Pediatrics

Subsidization of supermarkets may help reduce obesity risk in children

June 27, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

June 23, 2022
Improved glycemic control in type 1 diabetics on very low-carbohydrate diets
Cardiology

Review suggests mixed evidence for relationship between food insecurity and childhood obesity

June 14, 2022
Cardiology

Associations remain inconclusive between religiosity and spirituality on medication adherence in cardiovascular disease

May 16, 2022
Next Post
Parental debt influences child socioemotional well-being

American Academy of Pediatrics calls for action on poverty

Placebo formulation impacts effectiveness of pain control in osteoarthritis

Vitamin D3 supplementation does not improve pain or cartilage thickness in knee osteoarthritis: The VIDEO trial

Nanoparticle delivery of aurora kinase inhibitor may improve tumor treatment [PreClinical]

2 Minute Medicine Rewind March 7, 2016

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.